Please select the option that best describes you:
How do you define "low-volume" intermediate risk prostate cancer that is appropriate for brachytherapy alone?
Specifically, what criteria do you use to quantify "low-volume" prostate cancer? What other criteria do you consider when defining low volume intermediate risk prostate cancer that can be considered for bracthy monotherapy?
Answer from: Radiation Oncologist at Community Practice
For prostate cancer the use of PSA, T-stage, and Gleason score have been used to create multiple different risk stratification schemes. That of @Anthony V. D'Amico, the NCCN, and the AJCC are all very similar. In addition, other methods such as the Memorial Sloan Kettering nomogram...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
@Daniel A. Hamstra has summed up the most relevant empiric evidence available to date. This provides the assurance that favorable-interm risk prostate cancers with good urinary function are generally good candidates for brachytherapy monotherapy. Yet, with regards to patients with more aggressi...
Answer from: Radiation Oncologist at Academic Institution
I would just say that probably any increase in risk factors increases risk. Perhaps even "secondary" gleason score, meaning if you had only a small core of G3+4 but the rest G3+3 your secondary score is 6 or if G4+3 but you had another G3+4 then your secondary is 3+4.
Also number of cores + is a mo...